PhytoMedical's Next-Generation Compounds Effective Against Cancer Cells
Posted on: Tuesday, 4 March 2008, 06:00 CST
PhytoMedical Technologies has reported positive results from new tests of the company's next generation anticancer compounds, which have demonstrated the ability to kill difficult-to-treat human cancer cells, including colon cancer cells and human glioblastoma cells related to brain cancer.
In important tests against a difficult-to-treat strain of human colon cancer cells (HCT116), scientists evaluated the performance of concentrated amounts of company's newest anticancer compounds. Researchers observed a 50% or greater cancer cell kill rate using these patented compounds, reporting excellent success in the company's second Phase tests where they have employed new, synthetic bis-acridines for the first time.
Greg Wujek, president and CEO of PhytoMedical, said: "Based on encouraging outcomes from early Phase one research into our first-generation anticancer compounds, we immediately bolstered our efforts and initiated tests of our next-generation compounds. These Phase two tests were specifically designed to target difficult-to-treat strains of human cancer cells, and the resulting outcomes have been very favorable."
Source: Datamonitor
Related Articles
- Magnum/SRI Releases Phase II Results of Custom Compound Tests
- Key Anti-Cancer Compound Found In Broccoli
- PhytoMedical's In Vivo Toxicity and Efficacy Tests on Human Colon Cancer Deliver Promising Results
- Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
- AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
- PhytoMedical's Patented Anti-Cancer Compounds Kill Lung Cancer Cells, a Significant New Finding
- NIH Awards Thermedical $3 Million for Cancer Therapy Testing
- Advaxis' Cervical Cancer Vaccine Approved for Human Testing
- US Researchers Find New Anti-Cancer Compounds
- Bionaut Pharmaceuticals and AnalytiCon Discovery Enter into a Lead Optimization Collaboration for a Novel Class of Anti-Cancer Compounds
 |
 |
User Comments (0)
RSS Feeds